Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL SKIN MICROBIOME MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL SKIN MICROBIOME MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 EPIDEMIOLOGY BASED MODEL
2.2.11 VENDOR SHARE ANALYSIS
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL SKIN MICROBIOME MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 REGULATORY SCENARIO
5.2 PESTEL ANALYSIS
5.3 PORTER’S 5 FORCES
5.4 REIMBURSMENT SCENARIO
6 INDUSTRY INSIGHTS
7 REGULATORY FRAMEWORK
8 GLOBAL SKIN MICROBIOME MARKET, BY PRODUCT
9 NOTE: MARKET VALUE, VOLUME AND ASP ANALYSIS WOULD BE PROVIDED FOR ALL SEGMENTS AND SUB-SEGMENTS OF PRODUCT)
9.1 OVERVIEW
9.2 PROBIOTIC
9.2.1 LACTOCOCCUS
9.2.1.1. TOPICAL
9.2.1.1.1. SPRAY
9.2.1.1.1.1 MARKET VALUE(USD MILLION)
9.2.1.1.1.2 MARKET VOLUME(UNITS)
9.2.1.1.1.3 AVERAGE SELLING PRICE(ASP)
9.2.1.1.2. SERUM
9.2.1.1.2.1 MARKET VALUE(USD MILLION)
9.2.1.1.2.2 MARKET VOLUME(UNITS)
9.2.1.1.2.3 AVERAGE SELLING PRICE(ASP)
9.2.1.1.3. MOISTURIZER
9.2.1.1.3.1 MARKET VALUE(USD MILLION)
9.2.1.1.3.2 MARKET VOLUME(UNITS)
9.2.1.1.3.3 AVERAGE SELLING PRICE(ASP)
9.2.1.1.4. OIL
9.2.1.1.4.1 MARKET VALUE(USD MILLION)
9.2.1.1.4.2 MARKET VOLUME(UNITS)
9.2.1.1.4.3 AVERAGE SELLING PRICE(ASP)
9.2.1.1.5. CLEANSER
9.2.1.1.5.1 MARKET VALUE(USD MILLION)
9.2.1.1.5.2 MARKET VOLUME(UNITS)
9.2.1.1.5.3 AVERAGE SELLING PRICE(ASP)
9.2.1.1.6. GELS
9.2.1.1.6.1 MARKET VALUE(USD MILLION)
9.2.1.1.6.2 MARKET VOLUME(UNITS)
9.2.1.1.6.3 AVERAGE SELLING PRICE(ASP)
9.2.1.1.7. MASKS
9.2.1.1.7.1 MARKET VALUE(USD MILLION)
9.2.1.1.7.2 MARKET VOLUME(UNITS)
9.2.1.1.7.3 AVERAGE SELLING PRICE(ASP)
9.2.1.1.8. PRIMERS
9.2.1.1.8.1 MARKET VALUE(USD MILLION)
9.2.1.1.8.2 MARKET VOLUME(UNITS)
9.2.1.1.8.3 AVERAGE SELLING PRICE(ASP)
9.2.1.1.9. OTHERS
9.2.1.2. ORAL
9.2.1.3. OTHERS
9.2.2 BIFIDOBACTERIUM
9.2.2.1. TOPICAL
9.2.2.1.1. SPRAY
9.2.2.1.1.1 MARKET VALUE(USD MILLION)
9.2.2.1.1.2 MARKET VOLUME(UNITS)
9.2.2.1.1.3 AVERAGE SELLING PRICE(ASP)
9.2.2.1.2. SERUM
9.2.2.1.2.1 MARKET VALUE(USD MILLION)
9.2.2.1.2.2 MARKET VOLUME(UNITS)
9.2.2.1.2.3 AVERAGE SELLING PRICE(ASP)
9.2.2.1.3. MOISTURIZER
9.2.2.1.3.1 MARKET VALUE(USD MILLION)
9.2.2.1.3.2 MARKET VOLUME(UNITS)
9.2.2.1.3.3 AVERAGE SELLING PRICE(ASP)
9.2.2.1.4. OIL
9.2.2.1.4.1 MARKET VALUE(USD MILLION)
9.2.2.1.4.2 MARKET VOLUME(UNITS)
9.2.2.1.4.3 AVERAGE SELLING PRICE(ASP)
9.2.2.1.5. CLEANSER
9.2.2.1.5.1 MARKET VALUE(USD MILLION)
9.2.2.1.5.2 MARKET VOLUME(UNITS)
9.2.2.1.5.3 AVERAGE SELLING PRICE(ASP)
9.2.2.1.6. GELS
9.2.2.1.6.1 MARKET VALUE(USD MILLION)
9.2.2.1.6.2 MARKET VOLUME(UNITS)
9.2.2.1.6.3 AVERAGE SELLING PRICE(ASP)
9.2.2.1.7. MASKS
9.2.2.1.7.1 MARKET VALUE(USD MILLION)
9.2.2.1.7.2 MARKET VOLUME(UNITS)
9.2.2.1.7.3 AVERAGE SELLING PRICE(ASP)
9.2.2.1.8. PRIMERS
9.2.2.1.8.1 MARKET VALUE(USD MILLION)
9.2.2.1.8.2 MARKET VOLUME(UNITS)
9.2.2.1.8.3 AVERAGE SELLING PRICE(ASP)
9.2.2.1.9. OTHERS
9.2.2.2. ORAL
9.2.2.3. OTHERS
9.2.3 STREPTOCOCCUS THERMOPHILUS
9.2.3.1. TOPICAL
9.2.3.1.1. SPRAY
9.2.3.1.1.1 MARKET VALUE(USD MILLION)
9.2.3.1.1.2 MARKET VOLUME(UNITS)
9.2.3.1.1.3 AVERAGE SELLING PRICE(ASP)
9.2.3.1.2. SERUM
9.2.3.1.2.1 MARKET VALUE(USD MILLION)
9.2.3.1.2.2 MARKET VOLUME(UNITS)
9.2.3.1.2.3 AVERAGE SELLING PRICE(ASP)
9.2.3.1.3. MOISTURIZER
9.2.3.1.3.1 MARKET VALUE(USD MILLION)
9.2.3.1.3.2 MARKET VOLUME(UNITS)
9.2.3.1.3.3 AVERAGE SELLING PRICE(ASP)
9.2.3.1.4. OIL
9.2.3.1.4.1 MARKET VALUE(USD MILLION)
9.2.3.1.4.2 MARKET VOLUME(UNITS)
9.2.3.1.4.3 AVERAGE SELLING PRICE(ASP)
9.2.3.1.5. CLEANSER
9.2.3.1.5.1 MARKET VALUE(USD MILLION)
9.2.3.1.5.2 MARKET VOLUME(UNITS)
9.2.3.1.5.3 AVERAGE SELLING PRICE(ASP)
9.2.3.1.6. GELS
9.2.3.1.6.1 MARKET VALUE(USD MILLION)
9.2.3.1.6.2 MARKET VOLUME(UNITS)
9.2.3.1.6.3 AVERAGE SELLING PRICE(ASP)
9.2.3.1.7. MASKS
9.2.3.1.7.1 MARKET VALUE(USD MILLION)
9.2.3.1.7.2 MARKET VOLUME(UNITS)
9.2.3.1.7.3 AVERAGE SELLING PRICE(ASP)
9.2.3.1.8. PRIMERS
9.2.3.1.8.1 MARKET VALUE(USD MILLION)
9.2.3.1.8.2 MARKET VOLUME(UNITS)
9.2.3.1.8.3 AVERAGE SELLING PRICE(ASP)
9.2.3.1.9. OTHERS
9.2.3.2. ORAL
9.2.3.3. OTHERS
9.2.4 SACCHAROMYCES
9.2.4.1. TOPICAL
9.2.4.1.1. SPRAY
9.2.4.1.1.1 MARKET VALUE(USD MILLION)
9.2.4.1.1.2 MARKET VOLUME(UNITS)
9.2.4.1.1.3 AVERAGE SELLING PRICE(ASP)
9.2.4.1.2. SERUM
9.2.4.1.2.1 MARKET VALUE(USD MILLION)
9.2.4.1.2.2 MARKET VOLUME(UNITS)
9.2.4.1.2.3 AVERAGE SELLING PRICE(ASP)
9.2.4.1.3. MOISTURIZER
9.2.4.1.3.1 MARKET VALUE(USD MILLION)
9.2.4.1.3.2 MARKET VOLUME(UNITS)
9.2.4.1.3.3 AVERAGE SELLING PRICE(ASP)
9.2.4.1.4. OIL
9.2.4.1.4.1 MARKET VALUE(USD MILLION)
9.2.4.1.4.2 MARKET VOLUME(UNITS)
9.2.4.1.4.3 AVERAGE SELLING PRICE(ASP)
9.2.4.1.5. CLEANSER
9.2.4.1.5.1 MARKET VALUE(USD MILLION)
9.2.4.1.5.2 MARKET VOLUME(UNITS)
9.2.4.1.5.3 AVERAGE SELLING PRICE(ASP)
9.2.4.1.6. GELS
9.2.4.1.6.1 MARKET VALUE(USD MILLION)
9.2.4.1.6.2 MARKET VOLUME(UNITS)
9.2.4.1.6.3 AVERAGE SELLING PRICE(ASP)
9.2.4.1.7. MASKS
9.2.4.1.7.1 MARKET VALUE(USD MILLION)
9.2.4.1.7.2 MARKET VOLUME(UNITS)
9.2.4.1.7.3 AVERAGE SELLING PRICE(ASP)
9.2.4.1.8. PRIMERS
9.2.4.1.8.1 MARKET VALUE(USD MILLION)
9.2.4.1.8.2 MARKET VOLUME(UNITS)
9.2.4.1.8.3 AVERAGE SELLING PRICE(ASP)
9.2.4.1.9. OTHERS
9.2.4.2. ORAL
9.2.4.3. OTHERS
9.2.5 LACTOBACILLUS
9.2.5.1. TOPICAL
9.2.5.1.1. SPRAY
9.2.5.1.1.1 MARKET VALUE(USD MILLION)
9.2.5.1.1.2 MARKET VOLUME(UNITS)
9.2.5.1.1.3 AVERAGE SELLING PRICE(ASP)
9.2.5.1.2. SERUM
9.2.5.1.2.1 MARKET VALUE(USD MILLION)
9.2.5.1.2.2 MARKET VOLUME(UNITS)
9.2.5.1.2.3 AVERAGE SELLING PRICE(ASP)
9.2.5.1.3. MOISTURIZER
9.2.5.1.3.1 MARKET VALUE(USD MILLION)
9.2.5.1.3.2 MARKET VOLUME(UNITS)
9.2.5.1.3.3 AVERAGE SELLING PRICE(ASP)
9.2.5.1.4. OIL
9.2.5.1.4.1 MARKET VALUE(USD MILLION)
9.2.5.1.4.2 MARKET VOLUME(UNITS)
9.2.5.1.4.3 AVERAGE SELLING PRICE(ASP)
9.2.5.1.5. CLEANSER
9.2.5.1.5.1 MARKET VALUE(USD MILLION)
9.2.5.1.5.2 MARKET VOLUME(UNITS)
9.2.5.1.5.3 AVERAGE SELLING PRICE(ASP)
9.2.5.1.6. GELS
9.2.5.1.6.1 MARKET VALUE(USD MILLION)
9.2.5.1.6.2 MARKET VOLUME(UNITS)
9.2.5.1.6.3 AVERAGE SELLING PRICE(ASP)
9.2.5.1.7. MASKS
9.2.5.1.7.1 MARKET VALUE(USD MILLION)
9.2.5.1.7.2 MARKET VOLUME(UNITS)
9.2.5.1.7.3 AVERAGE SELLING PRICE(ASP)
9.2.5.1.8. PRIMERS
9.2.5.1.8.1 MARKET VALUE(USD MILLION)
9.2.5.1.8.2 MARKET VOLUME(UNITS)
9.2.5.1.8.3 AVERAGE SELLING PRICE(ASP)
9.2.5.1.9. OTHERS
9.2.5.2. ORAL
9.2.5.3. OTHERS
9.2.6 LEUCONOSTOC
9.2.6.1. TOPICAL
9.2.6.1.1. SPRAY
9.2.6.1.1.1 MARKET VALUE(USD MILLION)
9.2.6.1.1.2 MARKET VOLUME(UNITS)
9.2.6.1.1.3 AVERAGE SELLING PRICE(ASP)
9.2.6.1.2. SERUM
9.2.6.1.2.1 MARKET VALUE(USD MILLION)
9.2.6.1.2.2 MARKET VOLUME(UNITS)
9.2.6.1.2.3 AVERAGE SELLING PRICE(ASP)
9.2.6.1.3. MOISTURIZER
9.2.6.1.3.1 MARKET VALUE(USD MILLION)
9.2.6.1.3.2 MARKET VOLUME(UNITS)
9.2.6.1.3.3 AVERAGE SELLING PRICE(ASP)
9.2.6.1.4. OIL
9.2.6.1.4.1 MARKET VALUE(USD MILLION)
9.2.6.1.4.2 MARKET VOLUME(UNITS)
9.2.6.1.4.3 AVERAGE SELLING PRICE(ASP)
9.2.6.1.5. CLEANSER
9.2.6.1.5.1 MARKET VALUE(USD MILLION)
9.2.6.1.5.2 MARKET VOLUME(UNITS)
9.2.6.1.5.3 AVERAGE SELLING PRICE(ASP)
9.2.6.1.6. GELS
9.2.6.1.6.1 MARKET VALUE(USD MILLION)
9.2.6.1.6.2 MARKET VOLUME(UNITS)
9.2.6.1.6.3 AVERAGE SELLING PRICE(ASP)
9.2.6.1.7. MASKS
9.2.6.1.7.1 MARKET VALUE(USD MILLION)
9.2.6.1.7.2 MARKET VOLUME(UNITS)
9.2.6.1.7.3 AVERAGE SELLING PRICE(ASP)
9.2.6.1.8. PRIMERS
9.2.6.1.8.1 MARKET VALUE(USD MILLION)
9.2.6.1.8.2 MARKET VOLUME(UNITS)
9.2.6.1.8.3 AVERAGE SELLING PRICE(ASP)
9.2.6.1.9. OTHERS
9.2.6.2. ORAL
9.2.6.3. OTHERS
9.3 PREBIOTIC
9.3.1 PLANT BASED
9.3.2 SYNTHESIZED
9.4 OTHERS
10 GLOBAL SKIN MICROBIOME MARKET, BY TYPES
10.1 OVERVIEW
10.2 RESIDENT MICROORGANISMS
10.3 TRANSIENT BACTERIA
11 GLOBAL SKIN MICROBIOME MARKET, BY DISEASE
11.1 OVERVIEW
11.2 ATOPIC DERMATITIS
11.3 ACNE VULGARIS
11.4 ROSACEA
11.5 PSORIASIS VULGARIS
11.6 ATOPIC DERMATITIS
11.7 PEMPHIGUS
11.8 ALOPECIA AREATA
11.9 EPIDERMOLYSIS BULLOSA
11.1 SCLERODERMA
11.11 ICHTHYOSIS
11.12 VITILIGO
11.13 OTHERS
12 GLOBAL SKIN MICROBIOME MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 TOPICAL
12.3 ORAL
13 GLOBAL SKIN MICROBIOME MARKET, BY SKIN TYPE
13.1 OVERVIEW
13.2 MOIST SKIN
13.2.1 TOPICAL
13.2.2 ORAL
13.3 DRY SKIN
13.3.1 TOPICAL
13.3.2 ORAL
13.4 OILY SKIN
13.4.1 TOPICAL
13.4.2 ORAL
13.5 OTHER
14 GLOBAL SKIN MICROBIOME MARKET, BY POPULATION TYPE
14.1 OVERVIEW
14.2 MEN
14.3 WOMEN
14.4 CHILDREN
15 GLOBAL SKIN MICROBIOME MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 DERMATOLOGY HOSPITAL
15.4 SPECILITY HOSPITALS
15.5 SPA OR SALON
15.6 BEAUTY PARLERS
15.7 HOME HEALTHCARE
15.8 OTHERS
16 GLOBAL SKIN MICROBIOME MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 HOSPITAL PHARMACIES
16.3 RETAIL SALES
16.3.1 DRUG STORE
16.3.2 COMPANY OWNED BRANDED STORE
16.3.3 MULTIBRANDED STORE
16.3.4 OTHER
16.4 ONLINE SALES
16.4.1 COMPANY OWNED WEBSITE
16.4.2 E- COMMERCE WEBSITES
16.4.3 ONLINE PHARMACY
16.5 OTHER
17 GLOBAL SKIN MICROBIOME MARKET, COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: GLOBAL
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
17.3 COMPANY SHARE ANALYSIS: EUROPE
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
17.5 MERGERS & ACQUISITIONS
17.6 NEW PRODUCT DEVELOPMENT & APPROVALS
17.7 EXPANSIONS
17.8 REGULATORY CHANGES
17.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
17.1
18 GLOBAL SKIN MICROBIOME MARKET, BY COUNTRY
GLOBAL SKIN MICROBIOME MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
18.1 NORTH AMERICA
18.1.1 U.S.
18.1.2 CANADA
18.1.3 MEXICO
18.2 EUROPE
18.2.1 GERMANY
18.2.2 U.K.
18.2.3 ITALY
18.2.4 FRANCE
18.2.5 SPAIN
18.2.6 RUSSIA
18.2.7 SWITZERLAND
18.2.8 TURKEY
18.2.9 BELGIUM
18.2.10 NETHERLANDS
18.2.11 DENMARK
18.2.12 SWEDEN
18.2.13 POLAND
18.2.14 NORWAY
18.2.15 FINLAND
18.2.16 REST OF EUROPE
18.3 ASIA-PACIFIC
18.3.1 JAPAN
18.3.2 CHINA
18.3.3 SOUTH KOREA
18.3.4 INDIA
18.3.5 SINGAPORE
18.3.6 THAILAND
18.3.7 INDONESIA
18.3.8 MALAYSIA
18.3.9 PHILIPPINES
18.3.10 AUSTRALIA
18.3.11 NEW ZEALAND
18.3.12 VIETNAM
18.3.13 TAIWAN
18.3.14 REST OF ASIA-PACIFIC
18.4 SOUTH AMERICA
18.4.1 BRAZIL
18.4.2 ARGENTINA
18.4.3 REST OF SOUTH AMERICA
18.5 MIDDLE EAST AND AFRICA
18.5.1 SOUTH AFRICA
18.5.2 EGYPT
18.5.3 BAHRAIN
18.5.4 UNITED ARAB EMIRATES
18.5.5 KUWAIT
18.5.6 OMAN
18.5.7 QATAR
18.5.8 SAUDI ARABIA
18.5.9 REST OF MEA
18.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
19 GLOBAL SKIN MICROBIOME MARKET, SWOT AND DBMR ANALYSIS
20 GLOBAL SKIN MICROBIOME MARKET, COMPANY PROFILE
20.1 AURELIA LONDON
20.1.1 COMPANY OVERVIEW
20.1.2 REVENUE ANALYSIS
20.1.3 GEOGRAPHIC PRESENCE
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPMENTS
20.2 GALLINÉE.
20.2.1 COMPANY OVERVIEW
20.2.2 REVENUE ANALYSIS
20.2.3 GEOGRAPHIC PRESENCE
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPMENTS
20.3 DAKOTA BIOTECH
20.3.1 COMPANY OVERVIEW
20.3.2 REVENUE ANALYSIS
20.3.3 GEOGRAPHIC PRESENCE
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPMENTS
20.4 MOTHER DIRT'S
20.4.1 COMPANY OVERVIEW
20.4.2 REVENUE ANALYSIS
20.4.3 GEOGRAPHIC PRESENCE
20.4.4 PRODUCT PORTFOLIO
20.4.5 RECENT DEVELOPMENTS
20.5 ESSE SKINCARE
20.5.1 COMPANY OVERVIEW
20.5.2 REVENUE ANALYSIS
20.5.3 GEOGRAPHIC PRESENCE
20.5.4 PRODUCT PORTFOLIO
20.5.5 RECENT DEVELOPMENTS
20.6 S-BIOMEDIC
20.6.1 COMPANY OVERVIEW
20.6.2 REVENUE ANALYSIS
20.6.3 GEOGRAPHIC PRESENCE
20.6.4 PRODUCT PORTFOLIO
20.6.5 RECENT DEVELOPMENTS
20.7 ELIZABETH ARDEN
20.7.1 COMPANY OVERVIEW
20.7.2 REVENUE ANALYSIS
20.7.3 GEOGRAPHIC PRESENCE
20.7.4 PRODUCT PORTFOLIO
20.7.5 RECENT DEVELOPMENTS
20.8 YUN PEROBIOTHERAPY
20.8.1 COMPANY OVERVIEW
20.8.2 REVENUE ANALYSIS
20.8.3 GEOGRAPHIC PRESENCE
20.8.4 PRODUCT PORTFOLIO
20.8.5 RECENT DEVELOPMENTS
20.9 TULA LIFE, INC
20.9.1 COMPANY OVERVIEW
20.9.2 REVENUE ANALYSIS
20.9.3 GEOGRAPHIC PRESENCE
20.9.4 PRODUCT PORTFOLIO
20.9.5 RECENT DEVELOPMENTS
20.1 THE BEAUTY CHEF.
20.10.1 COMPANY OVERVIEW
20.10.2 REVENUE ANALYSIS
20.10.3 GEOGRAPHIC PRESENCE
20.10.4 PRODUCT PORTFOLIO
20.10.5 RECENT DEVELOPMENTS
20.11 L’OREAL PARIS
20.11.1 COMPANY OVERVIEW
20.11.2 REVENUE ANALYSIS
20.11.3 GEOGRAPHIC PRESENCE
20.11.4 PRODUCT PORTFOLIO
20.11.5 RECENT DEVELOPMENTS
20.12 CLINIQUE LABORATORIES, LLC.
20.12.1 COMPANY OVERVIEW
20.12.2 REVENUE ANALYSIS
20.12.3 GEOGRAPHIC PRESENCE
20.12.4 PRODUCT PORTFOLIO
20.12.5 RECENT DEVELOPMENTS
20.13 LA ROCHE-POSAY
20.13.1 COMPANY OVERVIEW
20.13.2 REVENUE ANALYSIS
20.13.3 GEOGRAPHIC PRESENCE
20.13.4 PRODUCT PORTFOLIO
20.13.5 RECENT DEVELOPMENTS
20.14 BEBE & BELLA, LLC.
20.14.1 COMPANY OVERVIEW
20.14.2 REVENUE ANALYSIS
20.14.3 GEOGRAPHIC PRESENCE
20.14.4 PRODUCT PORTFOLIO
20.14.5 RECENT DEVELOPMENTS
20.15 AMOREPACIFIC,
20.15.1 COMPANY OVERVIEW
20.15.2 REVENUE ANALYSIS
20.15.3 GEOGRAPHIC PRESENCE
20.15.4 PRODUCT PORTFOLIO
20.15.5 RECENT DEVELOPMENTS
20.16 BELANO MEDICAL AG
20.16.1 COMPANY OVERVIEW
20.16.2 REVENUE ANALYSIS
20.16.3 GEOGRAPHIC PRESENCE
20.16.4 PRODUCT PORTFOLIO
20.16.5 RECENT DEVELOPMENTS
20.17 GLOWBIOTICS LLC
20.17.1 COMPANY OVERVIEW
20.17.2 REVENUE ANALYSIS
20.17.3 GEOGRAPHIC PRESENCE
20.17.4 PRODUCT PORTFOLIO
20.17.5 RECENT DEVELOPMENTS
20.18 AOBIOME
20.18.1 COMPANY OVERVIEW
20.18.2 REVENUE ANALYSIS
20.18.3 GEOGRAPHIC PRESENCE
20.18.4 PRODUCT PORTFOLIO
20.18.5 RECENT DEVELOPMENTS
20.19 LAFLORE
20.19.1 COMPANY OVERVIEW
20.19.2 REVENUE ANALYSIS
20.19.3 GEOGRAPHIC PRESENCE
20.19.4 PRODUCT PORTFOLIO
20.19.5 RECENT DEVELOPMENTS
20.2 ESTÉE LAUDER INC
20.20.1 COMPANY OVERVIEW
20.20.2 REVENUE ANALYSIS
20.20.3 GEOGRAPHIC PRESENCE
20.20.4 PRODUCT PORTFOLIO
20.20.5 RECENT DEVELOPMENTS
20.21 ALGENIST
20.21.1 COMPANY OVERVIEW
20.21.2 REVENUE ANALYSIS
20.21.3 GEOGRAPHIC PRESENCE
20.21.4 PRODUCT PORTFOLIO
20.21.5 RECENT DEVELOPMENTS
20.22 BEBE & BELLA
20.22.1 COMPANY OVERVIEW
20.22.2 REVENUE ANALYSIS
20.22.3 GEOGRAPHIC PRESENCE
20.22.4 PRODUCT PORTFOLIO
20.22.5 RECENT DEVELOPMENTS
20.23 DSM
20.23.1 COMPANY OVERVIEW
20.23.2 REVENUE ANALYSIS
20.23.3 GEOGRAPHIC PRESENCE
20.23.4 PRODUCT PORTFOLIO
20.23.5 RECENT DEVELOPMENTS
20.24 EMINENCE ORGANIC SKIN CARE
20.24.1 COMPANY OVERVIEW
20.24.2 REVENUE ANALYSIS
20.24.3 GEOGRAPHIC PRESENCE
20.24.4 PRODUCT PORTFOLIO
20.24.5 RECENT DEVELOPMENTS
20.25 BIOPHILE
20.25.1 COMPANY OVERVIEW
20.25.2 REVENUE ANALYSIS
20.25.3 GEOGRAPHIC PRESENCE
20.25.4 PRODUCT PORTFOLIO
20.25.5 RECENT DEVELOPMENTS
20.26 PIERRE FABRE GROUP
20.26.1 COMPANY OVERVIEW
20.26.2 REVENUE ANALYSIS
20.26.3 GEOGRAPHIC PRESENCE
20.26.4 PRODUCT PORTFOLIO
20.26.5 RECENT DEVELOPMENTS
20.27 SIOLTA THERAPEUTICS
20.27.1 COMPANY OVERVIEW
20.27.2 REVENUE ANALYSIS
20.27.3 GEOGRAPHIC PRESENCE
20.27.4 PRODUCT PORTFOLIO
20.27.5 RECENT DEVELOPMENTS
20.28 IORA INDIA
20.28.1 COMPANY OVERVIEW
20.28.2 REVENUE ANALYSIS
20.28.3 GEOGRAPHIC PRESENCE
20.28.4 PRODUCT PORTFOLIO
20.28.5 RECENT DEVELOPMENTS
20.29 PROTA SKINCARE
20.29.1 COMPANY OVERVIEW
20.29.2 REVENUE ANALYSIS
20.29.3 GEOGRAPHIC PRESENCE
20.29.4 PRODUCT PORTFOLIO
20.29.5 RECENT DEVELOPMENTS
20.3 SABINSA.
20.30.1 COMPANY OVERVIEW
20.30.2 REVENUE ANALYSIS
20.30.3 GEOGRAPHIC PRESENCE
20.30.4 PRODUCT PORTFOLIO
20.30.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
21 RELATED REPORTS
22 CONCLUSION
23 QUESTIONNAIRE
24 ABOUT DATA BRIDGE MARKET RESEARCH
